The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 821508.
Company Details
- Founded
- -
- Address
- Paris, Fr
- Industry
- Research
- Website
- https://cardiateam.eu/
- Keywords
- diabetes, heart failure, omics.
- HQ
- Paris
- Competitors
- Medical Device Developments, Terrain Biosciences, alpha:soft, European Nucleotide Archive, European Virus Bioinformatics Center, Imricor, NEPHRIX Biosolutions, iPAT - Institute for Particle Technology (Institut für Partikeltechnik), Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, Fogarty International Center at NIH.
Cardiateam Questions
Cardiateam's website is https://cardiateam.eu/
Cardiateam's LinkedIn profile is https://fr.linkedin.com/company/cardiateamimih2020
Cardiateam's industry is
Research
Cardiateam's top competitors are
Medical Device Developments,
Terrain Biosciences,
Alpha:soft,
European Nucleotide Archive,
European Virus Bioinformatics Center,
Imricor,
Nephrix Biosolutions,
Ipat - Institute For Particle Technology (Institut Für Partikeltechnik),
Friends Of The Global Fight Against Aids, Tuberculosis And Malaria,
Fogarty International Center At Nih.
Cardiateam's categories are Research
Cardiateam's founding year is 2019
